# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
BTIG analyst Thomas Shrader reiterates Alector (NASDAQ: ALEC) with a Buy and maintains $5 price target.
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Ed...
Alector (NASDAQ:ALEC) raises FY2025 sales outlook from $5.000 million-$15.000 million to $13.000 million-$18.000 million vs $12...
Alector (NASDAQ:ALEC) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.43) by 29...
Mizuho analyst Graig Suvannavejh upgrades Alector (NASDAQ:ALEC) from Neutral to Outperform and raises the price target from ...